Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3532071 | 1.00 | ALDH1A1 (0.41) | ALDH1A1HPGDHSD17B10EGLN3SMN1; SMN2 | |
| SCHEMBL3517992 | 0.89 | ALDH1A1 (0.49) | ALDH1A1HPGDHSD17B10EGLN3LMNA | |
| SCHEMBL3527378 | 0.88 | EGLN3 (0.51) | ALDH1A1HPGDEGLN3LMNA | |
| SCHEMBL3528567 | 0.88 | EGLN3 (0.51) | ALDH1A1HPGDEGLN3LMNA | |
| SCHEMBL3757575 | 0.82 | CYP3A4 (0.39) | ALDH1A1HPGDHSD17B10EGLN3SMN1; SMN2 | |
| SCHEMBL3518417 | 0.80 | DHODH (0.44) | ALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL3526144 | 0.80 | DHODH (0.44) | ALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL3756784 | 0.79 | NPC1 (0.48) | ALDH1A1HPGDHSD17B10EGLN3SMN1; SMN2 | |
| SCHEMBL3518485 | 0.79 | HPGD (0.43) | ALDH1A1HPGDHSD17B10EGLN3SMN1; SMN2 | |
| SCHEMBL3522102 | 0.78 | PPID (0.45) | ALDH1A1HPGDHSD17B10EGLN3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101983384-A | Prolyl hydroxylase inhibitors | SMITHKLINE BEECHAM CORP | 2011-03-02 | — | — | CN | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| EP-2227770-A2 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009073497-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | ALDH1A1 191/4885HPGD 51/4885HSD17B10 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.